Cargando…
First‐in‐Human Studies of Pharmacokinetics and Safety of Utreloxastat (PTC857), a Novel 15‐Lipooxygenase Inhibitor for the Treatment of Amyotrophic Lateral Sclerosis
Utreloxastat (PTC857) is a 15‐lipoxygenase inhibitor being developed to treat amyotrophic lateral sclerosis. This first‐in‐human study investigated the safety and pharmacokinetics of utreloxastat in healthy volunteers (N = 82) in a double‐blind, placebo‐controlled trial. The effects of a single asce...
Autores principales: | Gao, Lan, Giannousis, Peter, Thoolen, Martin, Kaushik, Diksha, Latham, Joey, Tansy, Aaron, Ma, Jiyuan, Johnston, Mayzie, Dali, Mandar, Golden, Lee, Klein, Matthew, Kong, Ronald, Trimmer, Jeffrey |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10107758/ https://www.ncbi.nlm.nih.gov/pubmed/36516010 http://dx.doi.org/10.1002/cpdd.1203 |
Ejemplares similares
-
Lipooxygenase inhibition in osteoarthritis: a potential symptomatic and disease modifying effect?
por: Dougados, Maxime
Publicado: (2008) -
Phase 1 Study of Safety, Tolerability, and Pharmacokinetics of PTC299, an Inhibitor of Stress‐Regulated Protein Translation
por: Weetall, Marla, et al.
Publicado: (2016) -
5-Lipooxygenase Derivatives as Serum Biomarkers of a Successful Dietary Intervention in Patients with NonAlcoholic Fatty Liver Disease
por: Banaszczak, Marcin, et al.
Publicado: (2020) -
Association between TNF-Alpha (-857) Gene Polymorphism and Susceptibility to Tuberculosis
por: Anoosheh, S, et al.
Publicado: (2011) -
Crystal structure and magnetic properties of LaCa(0.143 (4))O(0.857 (4))F(0.143 (4))Bi(0.857 (4))S(2)
por: Huang, Rongtie, et al.
Publicado: (2016)